Lorenza Rimassa· @LorenzaRimassa · X·· 2 days agoScore70
Body
Zev Wainberg presents subgroup analyses from phase 3 RASolute 302 study of #daraxonrasib in patients with previously treated metastatic #PDAC at #ESMO26 (part 1) #ESMOAmbassadors @myESMO
269 views · 6 likes · 6 reposts · 0 replies
Conference abstracts
LBA82matched by Proffered paper 1: Gastrointestinal tumour, upper digestive
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.orgSource: Lorenza Rimassa · x.com